DK1486211T3 - Sammensætninger til behandling af cancer ved anvendelse af vira - Google Patents

Sammensætninger til behandling af cancer ved anvendelse af vira

Info

Publication number
DK1486211T3
DK1486211T3 DK04017349T DK04017349T DK1486211T3 DK 1486211 T3 DK1486211 T3 DK 1486211T3 DK 04017349 T DK04017349 T DK 04017349T DK 04017349 T DK04017349 T DK 04017349T DK 1486211 T3 DK1486211 T3 DK 1486211T3
Authority
DK
Denmark
Prior art keywords
compositions
cancer
viruses
treatment
mammal
Prior art date
Application number
DK04017349T
Other languages
English (en)
Inventor
Kirk W Reichard
Robert M Lorence
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Application granted granted Critical
Publication of DK1486211T3 publication Critical patent/DK1486211T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04017349T 1993-04-30 1994-04-29 Sammensætninger til behandling af cancer ved anvendelse af vira DK1486211T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5551993A 1993-04-30 1993-04-30
PCT/US1994/004732 WO1994025627A1 (en) 1993-04-30 1994-04-29 Methods of treating and detecting cancer using viruses

Publications (1)

Publication Number Publication Date
DK1486211T3 true DK1486211T3 (da) 2009-01-19

Family

ID=21998395

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02026340T DK1314431T3 (da) 1993-04-30 1994-04-29 Oprensede sammensætninger af Newcastle disease virus
DK04017349T DK1486211T3 (da) 1993-04-30 1994-04-29 Sammensætninger til behandling af cancer ved anvendelse af vira
DK94916604T DK0696326T5 (da) 1993-04-30 1994-04-29 Anvendelse af NDV til fremstilling af et medikament til behandling af cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02026340T DK1314431T3 (da) 1993-04-30 1994-04-29 Oprensede sammensætninger af Newcastle disease virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94916604T DK0696326T5 (da) 1993-04-30 1994-04-29 Anvendelse af NDV til fremstilling af et medikament til behandling af cancer

Country Status (12)

Country Link
US (2) US7056689B1 (da)
EP (4) EP2009119A1 (da)
JP (3) JP4338781B2 (da)
AT (3) ATE411809T1 (da)
AU (1) AU699487B2 (da)
CA (1) CA2161671A1 (da)
DE (3) DE69435118D1 (da)
DK (3) DK1314431T3 (da)
ES (3) ES2315595T3 (da)
HK (1) HK1052871A1 (da)
PT (3) PT1486211E (da)
WO (1) WO1994025627A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009119A1 (en) * 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
IL135507A0 (en) * 1997-10-09 2001-05-20 Pro Virus Inc Treatment of neoplasms with viruses
FR2788099B1 (fr) 1999-01-06 2001-02-09 Vallourec Mannesmann Oil & Gas Assemblage filete de deux tubes metalliques a couple eleve de vissage
JP2003530301A (ja) * 1999-04-15 2003-10-14 ウェルスタット バイオロジクス コーポレイション ウイルスを用いた新生物の処置
AU2005201079C1 (en) * 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) 2000-05-03 2013-07-23 Oncolytics Biotech Inc. Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es) 2000-05-03 2003-04-23 Oncolytics Biotech Inc Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
HK1052950B (en) 2000-06-26 2005-06-24 Wellstat Biologics Corporation Purging of cells using viruses
AR035227A1 (es) 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
EP1385466B1 (en) 2001-05-11 2011-03-09 Wellstat Biologics Corporation Oncolytic virus therapy
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) * 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US20040005546A1 (en) 2002-02-28 2004-01-08 Oncolytics Biotech Inc. Use of ribozymes in the detection of adventitious agents
CA2374388C (en) 2002-02-28 2005-07-12 Matthew C. Coffey The use of ribozymes in the detection of adventitious agents
NZ537255A (en) 2002-06-21 2009-04-30 Wellstat Biologics Corp Administration of therapeutic viruses
AU2003287472A1 (en) * 2002-11-05 2004-06-03 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060099189A1 (en) * 2003-03-24 2006-05-11 Lorence Robert M Anti-cancer virus desensitization method
WO2005042737A1 (ja) * 2003-11-04 2005-05-12 Dnavec Research Inc. 遺伝子導入された樹状細胞の製造方法
US20060018884A1 (en) * 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
WO2006001120A1 (ja) * 2004-06-24 2006-01-05 Dnavec Research Inc. マイナス鎖rnaウイルスを含む抗癌剤
ATE540698T1 (de) * 2005-07-14 2012-01-15 Wellstat Biologics Corp Krebsbehandlung mit viren, fluoropyrimidinen und camptothecinen
KR101492643B1 (ko) 2005-12-02 2015-02-12 이칸 스쿨 오브 메디슨 엣 마운트 시나이 비-천연 표면 단백질을 제시하는 키메라 바이러스 및 그의용도
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
JP5547640B2 (ja) * 2008-09-16 2014-07-16 ジェノミディア株式会社 前立腺癌の治療・予防剤
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
EA038981B1 (ru) 2013-03-14 2021-11-17 Икан Скул Оф Медсин Эт Маунт Синай Вирусы болезни ньюкасла и их применение
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
CN121343934A (zh) 2017-05-10 2026-01-16 制药五有限责任公司 对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3577525A (en) 1964-07-01 1971-05-04 Cornell Res Foundation Inc Adenovirus vaccine against canine hepatitis
NL7111160A (da) 1971-03-09 1972-09-12
ZA754725B (en) 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
JPS5173117A (en) * 1974-12-19 1976-06-24 Handai Biseibutsubyo Kenkyukai Ganryohozaino seiho
US4108983A (en) 1976-06-01 1978-08-22 The Wistar Institute Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US4126671A (en) 1976-08-17 1978-11-21 Pitman-Moore, Inc. Method for detecting bovine leukemia viral infection
US4379839A (en) 1977-05-23 1983-04-12 The Trustees Of Columbia University In The City Of New York Method for detecting cancer
IT1117218B (it) 1979-05-18 1986-02-17 Depa Sas Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto
US4282315A (en) 1979-09-13 1981-08-04 Corning Glass Works Preparation of enriched whole virus radioligand
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4465769A (en) 1981-12-11 1984-08-14 The United States Of America As Represented By The Department Of Health And Human Services Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes
JPS58116422A (ja) 1981-12-28 1983-07-11 Green Cross Corp:The 抗腫瘍剤
US4582787A (en) 1982-12-30 1986-04-15 Frankel Jack W Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
US4571385A (en) 1983-06-27 1986-02-18 The United States Of America As Represented By The Department Of Health And Human Services Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
JPS6089755A (ja) 1983-07-01 1985-05-20 フイリツプ・ジヨン・ベア−ド 診断用試薬及びその製造法並びにそれを用いる診断法
US4647773A (en) 1984-04-23 1987-03-03 The United States Of America As Represented By The Department Of Health And Human Services Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS60249058A (ja) 1984-05-25 1985-12-09 Eisai Co Ltd Ａｔｌウイルス抗体の測定方法および試薬
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
US5075213A (en) 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
FR2593828B2 (fr) 1986-01-31 1990-05-04 Pasteur Institut Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
US4735895A (en) 1984-12-28 1988-04-05 Oncotech, Inc. Cancer susceptibility test
US4786590A (en) 1985-01-15 1988-11-22 California Institute Of Technology Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
GB8500918D0 (en) 1985-01-15 1985-02-20 Cancer Res Inst Viral isolates
US4970071A (en) 1985-01-18 1990-11-13 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
EP0252940A4 (en) 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Anti-sense rna for treatment of retroviral disease states.
AU602875B2 (en) 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4861720A (en) 1986-07-03 1989-08-29 Regents Of The University Of California Oncornavirus vaccines and feline alpha-type interferon
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
US4849334A (en) 1987-06-09 1989-07-18 Life Technologies, Inc. Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en) 1987-06-12 1990-03-13 Life Technologies, Inc. Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de) 1987-07-11 1989-01-19 Behringwerke Ag Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
DE68929343T2 (de) 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5077198A (en) 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
US5124148A (en) 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
FR2632956B2 (fr) 1988-05-13 1991-07-12 Pasteur Institut Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5057314A (en) 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
FR2639225B1 (fr) 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
US5169753A (en) 1989-06-05 1992-12-08 Genelabs Incorporated Method and kit for detecting human retrovirus
FR2656627B1 (fr) 1989-12-28 1992-04-17 Pasteur Institut Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
CN1054192A (zh) * 1990-02-26 1991-09-04 张炳团 人体内诱导干扰素的制造方法
US5739107A (en) * 1991-03-11 1998-04-14 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5195539A (en) * 1992-03-23 1993-03-23 Minnesota Mining And Manufacturing Company Earplug compression device
CA2132328C (en) 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
ATE199568T1 (de) 1993-02-16 2001-03-15 Onyx Pharma Inc Cytopatische viren zur therapie und prophylaxe der neoplasie
JPH08508641A (ja) 1993-03-16 1996-09-17 ブリテイツシユ・テクノロジー・グループ・リミテツド ウイルスタンパク質による免疫応答刺激
EP2009119A1 (en) * 1993-04-30 2008-12-31 Wellstat Biologics Corporation Compositions for treating cancer using viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU2003287472A1 (en) * 2002-11-05 2004-06-03 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeuthic viruses

Also Published As

Publication number Publication date
EP1314431A3 (en) 2003-06-18
DE69432409D1 (de) 2003-05-08
EP0696326A4 (en) 1997-08-20
JP4338781B2 (ja) 2009-10-07
ATE411809T1 (de) 2008-11-15
EP0696326B1 (en) 2003-04-02
ATE401092T1 (de) 2008-08-15
PT1314431E (pt) 2008-10-24
DE69435118D1 (de) 2008-08-28
AU6821394A (en) 1994-11-21
DE69432409T2 (de) 2003-12-24
EP2009119A1 (en) 2008-12-31
ES2196026T3 (es) 2003-12-16
DK0696326T3 (da) 2003-06-23
EP1314431A2 (en) 2003-05-28
ES2315595T3 (es) 2009-04-01
EP1486211A1 (en) 2004-12-15
EP1314431B1 (en) 2008-07-16
CA2161671A1 (en) 1994-11-10
US7736640B2 (en) 2010-06-15
PT1486211E (pt) 2009-02-02
AU699487B2 (en) 1998-12-03
JPH09503995A (ja) 1997-04-22
DK0696326T5 (da) 2003-07-14
ATE236271T1 (de) 2003-04-15
DE69435155D1 (de) 2008-12-04
EP1486211B1 (en) 2008-10-22
EP0696326A1 (en) 1996-02-14
US20060216310A1 (en) 2006-09-28
US7056689B1 (en) 2006-06-06
JP2005187484A (ja) 2005-07-14
DK1314431T3 (da) 2008-11-10
HK1052871A1 (en) 2003-10-03
WO1994025627A1 (en) 1994-11-10
ES2310580T3 (es) 2009-01-16
PT696326E (pt) 2003-08-29
JP2009149689A (ja) 2009-07-09

Similar Documents

Publication Publication Date Title
DK1486211T3 (da) Sammensætninger til behandling af cancer ved anvendelse af vira
DE69811062D1 (de) Polyaromatische antivirale zusammensetzungen
EA200300023A1 (ru) 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
EP0313305A3 (en) Photoprotection compositions comprising chelating agents
DK0604910T3 (da) Phosphonooxymethylethere af taxanderivater
DE69430611D1 (de) Phosphonooxymethyl oder Methylthiomethylether von Taxanderivaten als Antitumormittel
ID27457A (id) Komposisi untuk pengobatan hiv dan infeksi virus lainnya
ES2137225T3 (es) Eliminacion de anticuerpos de composiciones de derivados sanguineos reteniendo los factores de coagulacion.
DK1037650T3 (da) Præparater til behandling af Staphylococcus aureus-infektioner
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DE69915977D1 (de) Neuartige Heparin bindende Peptide
FI961380L (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitamiseksi
DK0513409T3 (da) Anvendelse af et mikrobicidt middel ved fremstilling af betontagsten
ES2154879T3 (es) Compuestos antiviricos.
TR200001290T2 (tr) Estrojen mahrumiyet sendromunu tedavi etmek için yararlı 2-aril-3-aroilbenzo(b) tiofenler.
ATE198070T1 (de) Antivirusverbindungen
ES2159815T3 (es) Compuestos antivirales.
ID25478A (id) Agonis 5-ht1f
DK0806411T3 (da) Antivirale forbindelser
BR9914480A (pt) Processo para a fabricação de absorvedores de uv de 1,3,5-triazina substituìda por 2-hidróxi-4-alcoxifenila ou 2,4-didroxifenila
SE8303886L (sv) Synergetisk antihypertensiv farmaceutisk komposition
ECSP941089A (es) Agentes arilantes